Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and...

Area of Science:

• Oncology
• Immunotherapy
• Cancer Research

Background:

• Non-small-cell lung cancer (NSCLC) treatment has evolved, with immune checkpoint inhibitors (ICIs) becoming standard for tumors lacking oncogenic drivers.
• ICIs show durable efficacy in a subset of NSCLC patients, often used as monotherapy or in combination with chemotherapy.
• Treatment selection is complex due to a lack of head-to-head trials comparing different ICI strategies.

Purpose of the Study:

• To review therapeutic alternatives for NSCLC patients progressing on ICIs.
• To summarize mechanisms of resistance and patterns of progression to ICIs.
• To describe novel approaches under clinical investigation for advanced NSCLC.

Main Methods:

• Literature review of clinical trials and research studies.
• Analysis of mechanisms of resistance to immune checkpoint inhibitors.
• Summary of ongoing clinical investigations for post-progression NSCLC treatment.

Main Results:

• Most NSCLC patients eventually progress despite advances in immunotherapy.
• Limited randomized controlled data exists to guide management after ICI progression, representing a significant unmet need.
• Understanding resistance mechanisms is crucial for developing effective subsequent therapies.

Conclusions:

• Effective strategies are needed for NSCLC patients who progress after initial immunotherapy.
• Further research and clinical trials are essential to address the unmet need in post-progression NSCLC management.
• Investigational approaches hold promise for improving outcomes in this patient population.